 AIM ImmunoTech Inc NYSE: AIM submitted a Pre-Investigational New Drug Application Pre-IND to the FDA for COVID-19 trials with Ampligen. The application is for two separate Phase 2 clinical studies to study the potential of Ampligen as both an infusion and an intranasal therapy for early-onset COVID-19. 